Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 159 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Suppurative Hidradenitis Clear all
Completed Not applicable Interventional

Physical Activity in Hidradenitis Suppurativa (HS)

NCT06015438
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Home Exercise Program, Short Exercise Program
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 4, 2026, 4:14 AM EDT
Withdrawn Phase 2 Interventional

Gentian Violet Treatment for Hidradenitis Suppurativa

NCT04388163
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Gentian Violet
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Tofacitinib for Immune Skin Conditions in Down Syndrome

NCT04246372
View directory record Official record
Conditions
Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa, Vitiligo, Psoriasis
Interventions
Tofacitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Early Phase 1 Interventional

Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa

NCT04979520
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
Brodalumab
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Dioxide Laser Versus Surgical Deroofing

NCT02163746
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
CO2 (carbon dioxide) laser, Surgical Deroofing
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
13 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 4, 2026, 4:14 AM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Acne

NCT04214483
View directory record Official record
Conditions
Acne, Acne Vulgaris, Acne Keloidalis, Acne Keloid, Acne Conglobata, Acne Rosacea, Acne Inversa, Acne Cystic, Acne Pomade, Acne Indurata, Acne Papular, Acne Tropica, Acne Urticata, Acne Fulminans, Acne Follicular, Acne Tropicalis, Acne Detergicans, Acne Iodide, Acne Varioliformis
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 4, 2026, 4:14 AM EDT
Not yet recruiting Phase 2 Interventional

A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

NCT07766005
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
SPY072, Placebo, bimekizumab
Drug
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Irvine, California • Indianapolis, Indiana • Bowling Green, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03628924
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Largo, Florida • Ocala, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa

NCT04092452
View directory record Official record
Conditions
Acne Inversa
Interventions
PF-06650833, PF-06700841, PF-06826647, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
63
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 4, 2026, 4:14 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

NCT06921850
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
9 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Roseville, California • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 4, 2026, 4:14 AM EDT
Not listed No phase listed Observational

A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions

NCT05084417
View directory record Official record
Conditions
Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, Psoriasis
Interventions
N/A This is an observational study
Other
Lead sponsor
OM1, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 4, 2026, 4:14 AM EDT
Not yet recruiting Not applicable Interventional

Mediterranean Dietary Intervention for HS

NCT07800416
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Mediterranean Diet Counseling, Mediterranean Food Support
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 4, 2026, 4:14 AM EDT
Not listed Phase 2 Interventional

Treatment of Moderate Hidradenitis Suppurativa

NCT03910803
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Brodalumab
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

NCT04762277
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab - solution for infusion, Placebo matching spesolimab - solution for infusion, Spesolimab- solution for injection, Placebo matching to spesolimab- solution for injection
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Phase 3 Interventional

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04901195
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 4, 2026, 4:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical and Biological Characteristics of Hidradenitis Suppurativa

NCT03967600
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Aviclear for Hidradenitis Suppurativa (HS)

NCT06801795
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
AviClear
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 4, 2026, 4:14 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

To Determine the Efficacy of a Laser Device for the Treatment of Hidradenitis Suppurativa

NCT00367328
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
1320nm Nd: YAG nonablative laser
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 4, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional

Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa

NCT06555328
View directory record Official record
Conditions
Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
Interventions
CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment, HS low dose treatment, HS medium dose treatment, HS high dose treatment
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Fountain Valley, California • North Miami Beach, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

NCT04476043
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
INCB054707, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
25
States / cities
Hoover, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Not applicable Interventional

Study on the Effect of NdYag Laser for the Treatment of Hidradenitis Suppurativa

NCT00494351
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Long-pulsed Nd:YAG laser 1064 nm
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Anifrolumab for Hidradenitis Suppurativa

NCT06374212
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa, Hidradenitis
Interventions
Anifrolumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of Bermekimab in Patients With Hidradenitis Suppurativa

NCT03512275
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bermekimab Monoclonal Antibody 400 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 4, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3041658 in Adults With Hidradenitis Suppurativa

NCT04493502
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Placebo, LY3041658
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Rogers, Arkansas • Fountain Valley, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 4, 2026, 4:14 AM EDT